[ORIGINAL ARTICLE]

The Diagnosis of Drug-induced Liver Injury: Current Diagnostic Ability and Future Challenges of the Digestive Disease Week-Japan 2004 Scale 15 Years after Its Proposal

Masaaki Watanabe¹, Akitaka Shibuya², Hiroaki Yokomori³ and Wasaburo Koizumi⁴

Abstract:

Objective This study examined whether or not the Digestive Disease Week-Japan (DDW-J) 2004 scale proposed over 15 years ago can be applied to current cases of drug-induced liver injury (DILI).

Methods The new patients group included 125 patients from 2012 to 2019 and was divided into 2 subgroups: 96 patients in the new DILI group and 29 patients in the new non-DILI group. Similarly, the old patients group included 105 patients from 1997 to 2002 and was divided into 2 subgroups: 59 patients in the old DILI group and 46 patients in the old non-DILI group. Patients were assessed by the DDW-J 2004 scale; those with a score ≥ 3 were defined as having DILI.

Results The total score of the new DILI group was significantly lower than that of the old DILI group [6 (1-11) vs. 6 (3-9), $p=0.004$]. The sensitivity, specificity, positive predictive value, and negative predictive value (NPV) were 94.8%, 65.6%, 90.1%, and 79.2%, respectively, in the new patients group and 100%, 91.4%, 93.7%, and 100%, respectively, in the old patients group. The specificity and NPV of the new patients group were significantly lower than those of the old patients group.

Conclusion The DDW-J 2004 scale maintains a stable diagnostic ability for DILI, regardless of differences in eras and verification methods. However, differential diagnoses can affect the scoring, and new types of DILI, such as immune-related adverse events, must be addressed. Therefore, upgrading the scale should be considered.

Key words: adverse effect, diagnosis, Digestive Disease Week-Japan 2004 scale, drug-induced liver injury, Roussel Uclaf Causality Assessment Method

(Intern Med 60: 2557-2568, 2021)

(DOI: 10.2169/internalmedicine.6370-20)

Introduction

Drug-induced liver injury (DILI) due to prescription medicines, herbal medicines, over-the-counter drugs, health foods, and supplements is a liver disorder that is encountered on a daily basis. Most patients experience a good course due to the early, accurate diagnosis and discontinuation of the causative drug. However, some patients experience serious complications, such as fulminant hepatitis, requirement for liver transplant, and even death.

In Japan, the first diagnostic criteria for DILI were established in 1978 (1, 2). At that time, the principle pathogenic mechanism of DILI was thought to be an allergic reaction of the liver to drugs. Therefore, the criteria included the following immunoallergic features: a suggestive clinical course after drug administration; symptoms related to drug allergy, such as a fever, rash, and pruritus; eosinophilia $\geq 6\%$ in the peripheral blood; suggestive drug-induced lymphocyte stimulation test (DLST) results; and reappearance of liver injury following re-administration of the causal drug (1, 2). However, a national survey of DILI conducted in the latter

¹Department of Gastroenterology, Kitasato University Medical Center, Japan, ²Department of Risk Management and Health Care Administration, Kitasato University School of Medicine, Japan, ³Department of General Internal Medicine, Kitasato University Medical Center, Japan and ⁴Department of Gastroenterology, Kitasato University School of Medicine, Japan

Received: September 23, 2020; Accepted: January 25, 2021; Advance Publication by J-STAGE: March 15, 2021

Correspondence to Dr. Masaaki Watanabe, masaaki@kitasato-u.ac.jp

half of the 1990s in Japan revealed diversity in the mechanisms, causative drugs, time to the onset of DILI, and course after the onset (1, 3). The mechanisms underlying DILI are classified as direct hepatotoxicity and idiosyncratic hepatotoxicity (4, 5). In addition, indirect hepatotoxicity related to autoimmune mechanisms has come to be considered an emerging type (4). With this increased understanding of DILI, the previous diagnostic criteria, which were biased toward allergic features, became insufficient for diagnosing current DILI cases in Japan (1, 2).

Diagnostic criteria that could be used for any type of DILI were proposed by the International Consensus Meeting (ICM) in 1990 (6) and later revised to the Roussel Uclaf Causality Assessment Method (RUCAM) scale [previously called the Council for International Organizations of Medical Sciences (CIOMS) scale] in 1993 (7). The RUCAM scale is a scoring system that considers the relationship between the drug intake and onset, clinical course after cessation of the drug, risk factors, concomitant use of drugs, differential diagnosis of alternative liver diseases, any previous information regarding the hepatotoxicity of the drug, and response to unintentional reexposure (7).

Beginning in the early 2000s, there was an opportunity in Japan to propose a diagnostic scale based on the RUCAM scale that matches the actual condition of DILI in Japan. At Digestive Disease Week-Japan 2002 (DDW-J 2002) in Yokohama, Japan, which was jointly organized with the 6th General Meeting of the Japan Society of Hepatology (JSH) held in 2002, speakers from six institutions, including the author, presented data from actual DILI cases and designed a new draft of DILI diagnostic criteria (1). After further verification (2) and revision, the DDW-J 2004 scale was proposed with consensus at DDW-J 2004 in Fukuoka, Japan, jointly organized with the 8th General Meeting of the JSH in 2004 (8). The DDW-J 2004 scale was created and validated based on actual DILI cases available at that time. Of particular note, the DDW-J 2004 scale was designed to be easy and convenient for physicians other than hepatologists to use (8, 9). Since then, the DDW-J 2004 scale has been frequently cited as a common measure for DILI in Japan in both case reports and clinical research. The English version of the digital object identifier (DOI) is currently available online at *doi: 10.1111/j.1872-034X.2008.00400* (10).

However, a recent prospective study in Japan indicated that the clinical features of and pathogenic mechanism underlying DILI have changed (11, 12). In addition, many drugs with novel mechanisms of action were developed after the introduction of the DDW-J 2004 scale. Therefore, the DDW-J 2004 scale requires timely verification in order to support DILI in the current era.

The present study clarified the current clinical circumstances of DILI and evaluated whether or not the DDW-J 2004 scale, which was proposed over 15 years ago, can still be applied to current DILI cases.

Materials and Methods

Patients were retrospectively aggregated using the medical record management systems of two different hospitals during two different eras. This study includes two patient groups. The “new patients group” consists of individuals who were enrolled between February 2012 and August 2019 at Kitasato University Medical Center (Kitamoto, Saitama, Japan), and the “old patients group” consists of individuals who were enrolled between March 5, 1997, and December 26, 2002 (i.e., before the DDW-J 2004 scale was introduced) at Kitasato University East Hospital (Sagamihara, Kanagawa, Japan).

The new patients group and old patients group were further subclassified as the new DILI group, new non-DILI group, old DILI group, and old non-DILI group, respectively, by three experts according to whether they had DILI or another liver disease based on the definitions described below; H. Yokomori and A. Shibuya were involved in the assignment of patients into the new and old patients group, respectively, and M. Watanabe validated the selection of all patients. DILI was defined as liver injury associated with drug administration. The clinical features, clinical course, and differential diagnosis of other possible causes of liver injury were evaluated comprehensively, with the final diagnosis of the experts defined as the gold standard for DILI. This approach was based on a previous report that demonstrated the superiority of expert opinions in the diagnosis of DILI (13).

Non-DILI was defined as follows: liver disease that differed from DILI, was diagnosed by experts, and occurred in patients with a history of medication use for any symptoms or underlying illness at the time liver injury was first detected. Typical non-DILI included liver diseases listed as a target for differentiation on the DDW-J 2004 scale, namely acute viral hepatitis associated with hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), or cytomegalovirus (CMV); biliary tract disease; alcoholic liver disease (ALD); and shock liver. In addition, the following diseases that were suspected initially or confirmed later by experts were classified as non-DILI: chronic liver diseases, e.g. chronic viral hepatitis associated with HBV and HCV; autoimmune liver diseases, such as autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC); and metabolic disorders, such as nonalcoholic fatty liver disease (NAFLD).

Using this classification, the new patients group consisted of 96 patients with new DILI and 29 with new non-DILI, while the old patients group included 59 with old DILI and 46 with old non-DILI group (Fig. 1).

For each era, we created 2×2 contingency tables for DILI or non-DILI as defined by experts and for patients with scores ≥3 (possible or high possibility) or ≤2 (low possibility) as determined by the DDW-J 2004 scale. The sensitivity, specificity, positive predictive value (PPV), and negative pre-

Figure 1. Patients enrolled in this study. There was a 10- to 22-year gap between the 2 patient groups. **New patients group:** Patients with liver disease since 2012. **New DILI group:** Patients with drug-induced liver injury (DILI) since 2012. **New non-DILI group:** Patients who received medication for liver diseases other than DILI since 2012. **Old patients group:** Patients with liver disease before 2004. **Old DILI group:** Patients with DILI before 2002. **Old non-DILI group:** Patients who received medication for liver diseases other than DILI before 2002.

dictive value (NPV) for the new and old patients groups were calculated.

Data collection and limitations

This study was a retrospective study. The new and old patients groups were enrolled in two different hospitals. For the new patients group, data were collected from medical records. However, medical records from most of the patients in the old patients group were not generally available. Therefore, their data were acquired from previously published papers and the contents of previous conference presentations (2, 14, 15). Furthermore, the degree of liver damage in patients in the new patients group varied from mild to severe due to advances in medical record management systems. However, the data for the old patients group were primarily collected from patients who were hospitalized.

Statistical analyses

Categorical patient background variables and differences in sensitivity, specificity, PPV, and NPV were analyzed by Fisher's exact test or χ^2 test. Quantitative patient background variables and scores calculated by the DDW-J 2004 scale were analyzed by the Mann-Whitney U test. All statistical tests were performed with the Ekuseru-Toukei 2015 software program (Social Survey Research Information, Tokyo, Japan).

Statement of ethics

To obtain patient consent, an opt-out method was adopted prior to inclusion in this study. This study was approved by a suitably constituted Ethics Committee at our facility and conformed to the provisions of the Declaration of Helsinki.

Results

Table 1 lists current and past DILI and non-DILI conditions as well as patient background characteristics.

The new patients group (including both the DILI and

non-DILI subgroups) was older than the old patients group. Serum levels of alanine aminotransferase (ALT) and total bilirubin were higher in the old DILI group than in the new DILI group. Regarding the DILI type, hepatocellular type was more commonly observed than the cholestatic or mixed type in the new DILI group.

Some differences in items that might influence the DDW-J 2004 scale scoring were observed. With respect to the period from drug exposure to the onset of liver injury, no differences between the new and old DILI groups were observed. In contrast, this period was less relevant to the course of DILI in the new non-DILI group than in the old non-DILI group. Regarding the onset pattern, onset during the administration of the causative drug was more predominant in the new patients group than in the old patients group. Regarding the course after cessation of the drug, the period from drug discontinuation to the improvement of liver injury was shorter in the new DILI group than in the old DILI group. With respect to risk factors, because no pregnant women were enrolled in this study, only a history of alcohol use was subject to review. There was no marked difference in the history of alcohol use between the new and old DILI groups. In contrast, patients in the new non-DILI group were more likely to have a history of alcohol use than those in the old non-DILI group, suggesting that ALD may have been more prevalent in this group than in others. Regarding the search for non-drug causes, the exclusion diagnoses for group I diseases (HAV, HBV, HCV, ALD, gallbladder and biliary tract disease, and shock liver) and group II diseases (EBV and CMV) specified in the DDW-J 2004 scale were compared. Patients in the new DILI group were less completely surveyed for group I and II diseases than those in the old DILI group. Previous information on drug hepatotoxicity was available for 88.7% of drugs but often unavailable for unidentified agents, such as dietary supplements. The frequency of eosinophilia did not differ markedly between the new and old DILI groups when patients without eosinophil counts were included. A DLST was per-

Table 1. Patient Backgrounds.

	New patients group		Old patients group		Differences (p value)	
	New DILI group	New non-DILI group	Old DILI group	Old non-DILI group	New DILI group vs. Old DILI group	New non-DILI group vs. Old non-DILI group
Number of patients	96	29	59	46		
Age, years	65 (18-91)	64 (27-82)	51 (15-81)	38 (15-83)	<0.001	<0.001
Male/female, n	46/50	12/17	29/30	23/23	1.000	0.487
ALT, IU/L	204 (37-3,214)	251 (18-4,090)	638 (45-5,180)	1,139 (172-8,320)	<0.001	<0.001
ALP, IU/L	507 (150-3,172)	460 (173-8,626)	462 (107-2,597)	452 (142-1,117)	0.854	0.543
Total bilirubin, mg/dL	1.1 (0.3-36)	N/A	1.8 (0.3-22.7)	N/A	0.022	N/A
γGTP, IU/L	214 (17-1,602)	N/A	240 (37-1,629)	N/A	0.063	N/A
Type of DILI, n						
Hepatocellular	57	18	16	18	<0.001	0.062
Cholestatic or mixed	39	11	43	28		
Number of cancer/non-cancer patients, n	10/86	11/18	0/59	0/46	0.014	1
Time to onset, days [†]	24 (1-1,439)	83 (0-1,990)	15 (1-322)	8 (2-368)	0.163	0.003
Drug was continued at onset, n	74	18	30	15	0.001	0.017
Drug was discontinued at onset, n	22	11	29	31		
Course after cessation of the drug, days [†]	14 (0-120)	14 (0-120)	17 (0-751)	15 (3-155)	0.035	0.040
Risk factors, n						
History of alcohol use	15	10	4	5	0.132	0.018
No history of alcohol use	81	19	55	41		
Search for non-drug causes, n						
Group I completion	46	15	44	42		
Group II completion	36	12	31	28		
Groups I and II completion	30	10	29	26	0.028	0.096
Groups I and II incompleteness	66	19	30	20		
Previous information on hepatotoxicity of the drug, n						
Presence	88	25	51	40	0.415	1.000
Absence	8	4	8	6		
Eosinophilia (≥6 %), n						
Presence	17	1	29	10	0.080	0.042
Absence	69	26	30	36		
	(unknown 10)	(unknown 2)				
Drug-induced lymphocyte stimulation test, n						
Performed	23	1	58	19	<0.001	<0.001
Not performed	73	28	1	27		
Positive or semi-positive	11 (47.9%)	0 (0%)	24 (41.4%)	0 (0%)	0.389	<0.001
Negative	12 (52.1%)	1 (100%)	34 (58.6%)	19 (100%)		
Response to unexpected readministration, n						
Presence	3	0	1	0	1.000	1.000
Absence	93	29	58	46		
Definitive diagnostic basis of DILI by experts, n						
Clinical course	80		27			
DLST	9		17			
Liver biopsy	5		14			
Re-administration of suspicious drugs	2		1			
Liver diseases in patients without DILI, n [‡]						
Non-alcoholic fatty liver disease		10 (4)		0		
Alcoholic liver disease		5 (2)		0		
Biliary tract disease		5 (0)		2 (0)		
Autoimmune hepatitis		4 (3)		2 (0)		
Viral hepatitis		4 (1)		41 (3)		
Shock liver		1 (0)		1 (1)		

[†] Patients with unknown data are excluded.[‡] Numbers in parentheses indicate the number of patients with a total score of ≥3.n: number of patients, ALT: alanine aminotransferase, ALP: alkaline phosphatase, γGTP: γ-glutamyl transpeptidase, DILI: drug-induced liver injury
Values are expressed as median (minimum - maximum), unless otherwise indicated.

Table 2. DDW-J 2004 Scale Score Items.

	New DILI group (%)	Old DILI group (%)	p value
1. Time to onset			
0 or 1	46 (47.9)	42 (71.2)	0.005
2	50 (52.1)	17 (28.8)	
2. Course after cessation of the drug			
0-2	75 (78.1)	55 (93.2)	0.014
3	21 (21.9)	4 (6.8)	
3. Risk factors (ethanol)			
0	81 (84.4)	55 (93.2)	0.132
1	15 (15.6)	4 (6.8)	
4. Search for non-drug causes			
-2-1	71 (74.0)	21 (35.6)	<0.001
2	25 (26.0)	38 (64.4)	
5. Previous information on hepatotoxicity of the drug			
0	8 (8.3)	8 (13.6)	0.415
1	88 (91.7)	51 (86.4)	
6. Eosinophilia [†]			
0	79 (82.3)	39 (66.1)	0.032
1	17 (17.7)	20 (33.9)	
7. Drug-induced lymphocyte stimulation test			
0	85 (88.6)	35 (59.3)	<0.001
1	1 (1.0)	7 (11.9)	
2	10 (10.4)	17 (28.8)	
8. Response to unexpected readministration			
0	93 (96.9)	58 (98.3)	1.000
3	3 (3.1)	1 (1.7)	

Values are expressed as number of patients (percent).

[†] The score for patients with unknown eosinophil count was set to 0.

formed in 98.4% of patients in the old DILI group but in only 24.0% of patients in the new DILI group. However, the positivity rate did not differ markedly between these groups. Suspected drugs were accidentally re-administered to only a few patients.

In the new DILI group, the most frequent diagnostic basis for the condition used by experts was the clinical course and a decrease in the number of liver biopsies. The reason for this decision was that the prevalence of mild DILI increased, and an invasive liver biopsy was avoided.

Regarding liver disease in new and old non-DILI patients, we noted a decrease in viral hepatitis in the new non-DILI group that was easily excluded by the DDW-J 2004 scale. All four relevant patients were diagnosed with acute hepatitis, including one associated with HBV and three associated with EBV. Viral hepatitis was more common in the old non-DILI group, including 13 cases due to HBV, 11 due to HAV, 10 due to EBV, 5 due to HCV, and 2 due to other causes. Of these 41 cases, 39 had acute hepatitis, and 2 had initially been diagnosed with chronic hepatitis C. Conversely, the in-

cidence of NAFLD and AIH, which were difficult to exclude using the DDW-J 2004 scale, were both increased in the new non-DILI group.

Table 2 shows differences in the scores of each diagnostic item of the DDW-J 2004 scale between the new and old DILI group. Although there was no marked difference in the time to the onset (Table 1), patients in the new DILI group showed a more typical course for DILI, so a larger percentage (52.1%) received the highest score possible (2 points) than in the old DILI group (28.8%). Similarly, patients in the new DILI group also had a more typical liver injury recovery course after cessation of the drug than those in the old DILI group, so more patients (21.9%) in the new DILI group received the highest score possible (3 points) than in the old DILI group (6.8%). No marked differences in the history of alcohol use were observed. In the new DILI group, searches for non-drug causes were often not completed, so only 26.0% of patients received the highest score possible (2 points). In both subgroups, many patients were scored for items related to previous information about hepa-

Figure 2. The comparison of the diagnostic ability of the DDW-J 2004 scale in two different eras. Bar graphs show the distributions of total scores of the four subgroups calculated by the DDW-J 2004 scale. The vertical and horizontal axes represent the number of patients and total score, respectively. The vertical dashed line is the border of DILI or non-DILI, defined by the DDW-J 2004 scale. Patients in the new DILI group had significantly lower total scores than those in the old DILI group. The new patients groups showed a sensitivity of 94.8% and a positive predictive value of 90.1%. However, the specificity and negative predictive value were significantly lower than those in the old patients group.

totoxicity associated with the drug. Regarding eosinophilia, 82.3% of patients in the new DILI group were not scored because they did not have eosinophilia or had not had eosinophil counts performed. Patients in the new DILI group did not have the opportunity to acquire points for the DLST item due to the low DLST execution rate. No marked differences between the two subgroups were observed with respect to scoring by response to unexpected readministration.

The total scores of the four subgroups and their distributions are shown in Fig. 2 and Table 3. The total score for the new DILI group was significantly lower than that for the old DILI group. Although the sensitivity and PPV remained high, the specificity and NPV were significantly lower in the new patients group than in the old patients group.

Table 4 list the suspicious drugs by subgroup. New drugs that were approved after the DDW-J 2004 scale was proposed were administered to 22 patients in the new DILI group and 6 in the new non-DILI group. No marked differences in the diagnostic ability of the DDW-J 2004 scale were observed between the 28 patients who received new drugs and 97 who received existing drugs in the new patients group (Table 5).

Discussion

Diagnostic ability of the DDW-J 2004 scale for current DILI

More than 15 years have passed since the DDW-J 2004 scale was proposed. In this study, the data from the new patients group and old patients group were separated by at least 10 years and up to 22 years to verify the diagnostic ability of the DDW-J 2004 scale depending on the era. Differences between eras included changes in the understanding of the pathology of DILI, changes in patient background characteristics, identification of other liver diseases, achievement of more detailed differential diagnoses and use of DLST, changes in medical costs, approval of new drugs, and an increased awareness of DILI among clinicians. The results of this study suggest that, despite the changing circumstances surrounding DILI, the DDW-J 2004 scale can be applied to current DILI cases.

Impact of study limitations concerning patient backgrounds

The impact of the present study's limitations on our findings cannot be ignored. Differences in patient background characteristics and clinical findings influenced the DDW-J 2004 scale scoring. In this study, the severity of liver dam-

Table 3. Comparison of Diagnostic Ability of DDW-J 2004 Scale in Two Different Eras.

a) Difference in total score determined by the DDW-J 2004 scale			
	Total score	p value	
DILI group			
New DILI group	6 (1 - 11)	0.004	
Old DILI group	6 (3 - 9)		
Non-DILI group			
New non-DILI group	2 (-3 - 7)	0.144	
Old non-DILI group	1 (-3 - 3)		

Total scores are expressed as median (minimum - maximum).

b) 2×2 contingency tables of DILI or non-DILI defined by experts, and patients with a score ≥ 3 or ≤ 2 determined by the DDW-J 2004 scale for each era.			
Total score	≥ 3	≤ 2	
Subgroup			
New DILI group, n	91	5	
New non-DILI group, n	10	19	
Total score	≥ 3	≤ 2	
Subgroup			
Old DILI group, n	59	0	
Old non-DILI group, n	4	42	

n: number of patients

c) The sensitivity, specificity, positive predictive value, and negative predictive value for the new and old patient groups.			
	New patients group	Old patients group	p value
Sensitivity	94.8%	100%	0.086
Specificity	65.6%	91.4%	0.013
Positive predictive value	90.1%	93.7%	0.313
Negative predictive value	79.2%	100%	0.005

age at the onset was mild, and the period from discontinuation of the causative drug to the improvement of liver damage was shorter in the new DILI group than in the old DILI group. The time to the onset from the drug administration and clinical course after cessation of the drug were more consistent with DILI in the new DILI group than in the old DILI group. However, patients in the new and old patients groups were enrolled in two different hospitals, which may have influenced their backgrounds, such as the severity of liver damage, baseline diseases for which the drug was administered, and type of suspected drug. In addition, the old patients group did not include patients with cancer. While such patients were not intentionally excluded, liver dysfunction following the administration of anticancer agents might not have been registered as DILI in older medical record management systems. The factors described above are considered to be weaknesses of this retrospective study (16).

However, a review of previous peer-reviewed reports (10-12, 15) that mentioned scoring using the DDW-J 2004 scale in PubMed and the Igaku-Chuo-Zasshi database revealed that despite differences in eras, data collection

method, successfully performing a differential diagnosis and DLST, and types of facilities in which the studies were conducted, the median total DDWJ-2004 scale score was 6 or 7 among patients with DILI, suggesting high sensitivity (Table 6). Concerning the type of DILI, which can also influence the time to the onset and to the improvement of DILI, the incidence of hepatocellular injury-type DILI has increased, as shown in a recent report (12).

Changes in other liver diseases and achievement of a differential diagnosis and DLST

Changes were also observed in the list of other liver diseases that require differentiation from DILI. The DDW-J 2004 scale allows the straightforward exclusion of common viral hepatitis, such as HAV, HBV, and HCV. However, changes in the conception and epidemiology of liver disease, such as hepatitis E (HEV), for which a biological examination had not been commercialized at the time; NAFLD, which was previously not well recognized among Japanese hepatologists at the time the DDW-J 2004 scale was proposed; and acute-onset AIH (17, 18), which remains difficult

Table 4. Suspicious Drugs.

I. New patients group				
	New DILI group		New non-DILI group	
	Number	Name of suspicious drug	Number	Name of suspicious drug
Anti-allergy drugs	3 (0)	cetirizine hydrochloride, pranlukast hydrate, olopatadine hydrochloride	0	
Anticancer drugs	6 (3)	<i>axitinib</i> , <i>bevacizumab</i> , <i>regorafenib hydrate</i> , tamoxifen, tegafur/uracil×2	0	
Anti-inflammatory drugs	5 (1)	chlorpheniramine maleate, loxoprofen sodium hydrate×2, OTC, <i>tramadol hydrochloride/acetaminophen</i>	3 (0)	aspirin, OTC×2
Antilipidemic drugs	3 (0)	atorvastatin calcium×2, pitavastatin calcium	2 (1)	<i>fenofibrate</i> , pitavastatin calcium
Antimicrobial drugs	23 (4)	ampicillin sodium and sulbactam sodium, cefazolin sodium×3, cefcapene pivoxil hydrochloride hydrate×5, <i>cefditoren pivoxil</i> , cefotiam hydrochloride×2, ceftriaxone sodium×2, ciprofloxacin, clindamycin hydrochloride, <i>doripenem monohydrate</i> , isoniazid, meropenem, minocycline hydrochloride, <i>piperacillin sodium and tazobactam×2</i> , tosufloxacin tosilate	8 (2)	<i>cefditoren pivoxil</i> , <i>cefditoren pivoxil×2</i> , cefoperazone sodium and sulbactam sodium, ceftazidime pivoxil, clarithromycin, unknown×2
Drugs for the cardiovascular system	5 (2)	calcium polystyrene sulfonate, furosemide, <i>irbesartan and amlodipine besilate</i> , lomerizine hydrochloride, <i>olmesartan</i>	2 (2)	<i>telmisartan×2</i>
Chinese herbal medicines	9 (0)	Daisaiko, Hangeshashinto, Junchoto, Kakkon'oren'ogonto, Ninjinyoeito, Orengekuto, Ryugareikanto, Saikokaryukotsuboreito, Shakuyakukanzoto	2 (0)	Eppikajutsuto, Maoto
Dietary supplements	7 (0)	Details are unknown.	2 (0)	Details are unknown.
Drugs for the gastrointestinal system	6 (2)	antibiotics-resistant lactic acid bacteriae, metoclopramide hydrochloride, mosapride citrate dihydrate, sennosides, <i>vonoprazan fumarate×2</i>	1 (0)	rebamipide
Hematopoietic and anticoagulant drugs	1 (1)	<i>clopidogrel</i>	0	
Hormonal agents	3 (0)	conjugated estrogens, cyclofenil, levothyroxine sodium	0	
Metabolic agents	10 (6)	<i>benzbromarone</i> , disulfiram, <i>febuxostat</i> , <i> fingolimod hydrochloride</i> , glimepiride, glycyrrhizic acid, <i>iron sucrose</i> , <i>linagliptin</i> , methotrexate, <i>mitiglinide calcium dihydrate</i> , betahistine mesilate, carbamazepine, carbidopa hydrate and levodopa×2, donepezil hydrochloride, <i>escitalopram oxalate</i> , ifenprodil tartrate, lorazepam, phenytoin, <i>pregabalin</i> , tranilast, valproate sodium,	2 (0)	glimepiride, sodium risedronate hemipentahydrate
Drugs for psychiatric and neurological systems	12 (2)	betahistine mesilate, carbamazepine, carbidopa hydrate and levodopa×2, donepezil hydrochloride, <i>escitalopram oxalate</i> , ifenprodil tartrate, lorazepam, phenytoin, <i>pregabalin</i> , tranilast, valproate sodium,	4 (0)	alprazolam, betahistine mesilate, phenytoin, tranilast
Drugs for a urogenital system	2 (1)	flavoxate hydrochloride, <i>mirabegron</i>	1 (1)	<i>tamsulosin hydrochloride</i>
Others	1 (0)	some kind of food	2 (0)	some kind of food×2

Numbers in parentheses indicate new drugs approved after introduction of the DDW-J 2004 scale. The new drugs are shown in italic and bold font.

OTC: over-the-counter drug

to diagnose even by hepatologists, might affect the diagnostic specificity and NPV of the DDW-J 2004 scale.

In the new DILI group, most patients were tested for HBV and HCV. The exclusion of ALD by history taking and shock liver by a physical examination was also sufficient. However, examinations of biliary tract disease by imaging tests and of virus-related markers for HAV, EBV, and CMV were sometimes omitted. The number of patients who received DLST was also small.

There is no definitive biomarker for the diagnosis of DILI, so the differential diagnosis from other liver diseases and DLST is important and can affect the diagnostic ability of the DDW-J 2004 scale. However, high diagnostic costs cannot be ignored and might result in hesitation to make a detailed differential diagnosis and perform DLST.

Diagnostic ability of the DDW-J 2004 scale for new drugs and new types of DILI

Since the proposal of the DDW-J 2004 scale, numerous drugs with novel mechanisms of action and effects, which have been adopted as major treatments for common diseases and intractable disease in various body systems, have been developed. The new patients group in the present study received some of these new drugs, and the diagnostic potential of DDW-J 2004 scale for DILI caused by these new drugs was satisfied. Nevertheless, the new DILI group included two patients who experienced tamoxifen- (one patient) and estrogen-induced steatohepatitis (one patient) (19), which were diagnosed by experts. However, the cases were each given a score of 2 points (low possibility) on the DDW-J 2004 scale. It may be difficult to diagnose drug-induced steatohepatitis using the DDW-J 2004 scale, the concept and

Table 4. Suspicious Drugs. (Continued)

II. Old patients group				
		Old DILI group		
	Number	Name of suspicious drug	Number	Name of suspicious drug
Anti-allergy drugs	3	dexchlorpheniramine maleate, mequitazine, phenylpropanolamine hydrochloride	1	mequitazine
Anticancer drugs	0		1	tegafur/uracil
Anti-inflammatory drugs	9	aspirin, cold remedy×3, ibuprofen, loxoprofen sodium hydrate, naproxen, OTC×2	19	aspirin×3, cold remedy×2, diclofenac sodium, ibuprofen, loxoprofen sodium hydrate×4, OTC×8
Antilipidemic drugs	1	atorvastatin calcium	0	
Antimicrobial drugs	8	cefcape pivoxil hydrochloride hydrate×2, cefozopran hydrochloride, cefpodoxime proxetil, clarithromycin, fleroxacin, isoniazid, minocycline hydrochloride	10	azithromycin hydrate, cefaclor, cefazolin sodium hydrate, cefdinir×2, cefotiam hydrochloride, clarithromycin, erythromycin, levofloxacin×2
Drugs for the cardiovascular system	1	propranolol hydrochloride	2	diltiazem hydrochloride, tocopherol ticotinate
Chinese herbal medicines	4	Hachimijiogan, Kakkonto×2, Mutsugan	0	
Dietary supplements	3	Details are unknown.	0	
Drugs for the gastrointestinal system	5	azulene sulfonate sodium and L-glutamine, cimetidine×2, ranitidine hydrochloride, teprenone	9	antibiotics-resistant lactic acid bacteria, cimetidine, domperidone, famotidine×2, infliximab, OTC×3
Hematopoietic and anticoagulant drugs	3	ticlopidine×3	0	
Hormonal agents	2	betamethasone, levonorgestrel	0	
Metabolic agents	3	allopurinol, camostat mesylate, tiopronin	1	mecobalamin
Drugs for psychiatric and neurological systems	10	chlorpromazine hydrochloride, halothane×2, methylphenidate hydrochloride, phenobarbital, setipiline maleate, tizanidine hydrochloride, tofisopam, tranilast, vegetamin	0	
Drugs for a urogenital system	1	tamsulosin hydrochloride	2	flavoxate hydrochloride, sildenafil citrate
Others	6	cough medicine×2, some kind of food×2, Kallidinogenase, OTC	1	theophylline

OTC: over-the-counter drug

Table 5. Differences in Total Score of Liver Injury Caused by New Drugs and Existing Drugs in the New Patients Group.

	Patients who received new drugs		Patients who received existing drugs	
	≥ 3	≤ 2	≥ 3	≤ 2
Total score				
Subgroup				
New DILI group, n	22	0	69	5
New non-DILI group, n	1	5	9	14

	Patients who received new drugs	Patients who received existing drugs	p value
Sensitivity	100 %	93.3 %	0.264
Specificity	83.4 %	60.9 %	0.302
Positive predictive value	95.7 %	88.5 %	0.284
Negative predictive value	100 %	73.7 %	0.274

n: number of patients

causative agent of which have already been recognized. Therefore, if the DDW-J 2004 scale is revised in the future, these drugs should be included. Furthermore, it should be noted that immune checkpoint inhibitors, which cause immune-related adverse events (irAEs) (4, 20), were not in-

cluded in this study. Other new drugs will continue to be developed, so it is necessary to constantly verify the validity of new drugs and add comments if any are missing to keep the scale updated.

Table 6. Review of Past Reports Showing Assessment Using the DDW-J 2004 Scale.

Past report		1	2	3	4
	Reference	15	10	11	12
Patients and methods	Study design	Prospective	Retrospective	Retrospective	Prospective
	Era of study	Between April and December in 2005	Between 2002 and 2006	Between 1997 and 2006	Between 2010 and 2018
	Setting	Single center; emergency center in an university hospital	Multicenter; 6 university hospitals and 1 general hospital	Multicenter; 19 university hospitals and 9 general hospitals	Multicenter; 22 university hospitals and 7 general hospitals
	Inclusion criteria and gold standard of DILI	DILI that occurred during treatment at the emergency center were observed Diagnosis was performed by experts	Diagnosis was performed by experts	The diagnosis of DILI was performed according to the following: clinical course after drug administration (60%), clinical course after drug discontinuation (54%), clinical symptoms (12%), sensitivity tests (17%), diagnostic criteria (50%), liver biopsy (21%), re-administration (1.3%), and exclusion criteria (23%)	Diagnosis was performed by experts; serum levels of ALT $\geq$ 150 U/L and/or ALP $\geq$ 2 $\times$ upper limit of normal were required
	Number of DILI patients	63	366	1,676	307
	Number of non-DILI patients (control)	42	N/A	N/A	N/A
	Liver diseases of patients in control groups	Gallbladder and biliary tract disease: 25, shock liver: 6, viral hepatitis: 5, alcoholic liver disease: 2, other: 4	N/A	N/A	N/A
	Age, years (range)	58 (12-94)	55 (16-92)	55 (12-99)	61 (17-86)
	Male/female	36/27	162/204	721/955	125/182
	Hepatocellular type/cholestatic or mixed type	25 (40%)/38 (60%)	216 (59%)/150 (41%)	59%/41%	64%/36%
Backgrounds of DILI patients	Causal drugs of DILI (top three)	Details were not disclosed in the emergency center, drugs targeting the neurological system (including psychiatric agents) and antimicrobial drugs often induced DILI; anti-cancer agents and health foods were not evaluated	Anti-inflammatory (18%) Drugs targeting the neurological system (including psychiatric agents) (9%) Drugs targeting the circulatory and respiratory systems (14%)	Antimicrobial drugs (14.3%) Drugs targeting the neurological system (including psychiatric agents) (10.1%) Dietary supplements (10.0%)	Anti-inflammatory drugs (11%) Antimicrobial drugs (11%) Anticancer drugs (10%)
	Time to onset from the beginning of the drug	4 (range, 0-8) days for hepatocellular type, 4 (range, 1-11) days for cholestatic type, and 6 (range, 2-34) days for mixed type	$\leq$ 7 days: 81 (22.1%) 8-14 days: 51 (13.9%) 15-30 days: 65 (17.8%) 31-60 days: 55 (15.0%) $\geq$ 61 days: 114 (31.1%)	$\leq$ 7 days: 411 (24.5%) 8-14 days: 228 (13.6%) 15-30 days: 347 (20.7%) 31-90 days: 354 (21.1%) $\geq$ 91 days: 262 (15.6%) unknown: 74 (4.4%)	$\leq$ 7 days: 19% 8-14 days: 10% 15-30 days: 24% 31-60 days: 18% 61-90 days: 8% $\geq$ 91 days: 21%
	Time to onset from cessation of the drug	2 (range, 1-3) days for hepatocellular type, 8 days for cholestatic type, and 4 (range, 1-5) days for mixed type	N/A	N/A	N/A
	Course after cessation of the drug	4 (range, 1-15) days for hepatocellular type, 7.5 (range, 2-49) days for cholestatic type, and 7 (range, 1-33) days for mixed type	N/A	N/A	N/A
	Number of patients in searches for non-drug causes (group I and II)	63 (100%)	N/A	N/A	N/A
	Eosinophilia ($\geq$ 6%)	7 (11%)	N/A	26%	27%
	Number of patients diagnosed as DLST/DLST positive	Not performed	DLST was performed in 198 (54%) cases, and was positive in 87 (44%)	DLST was performed in 60% of cases, and was positive in 33%	DLST was performed in 59% of cases, and was positive in 48% and semipositive in 3%
	Response to unexpected re-administration	3 (4.8%)	N/A	N/A	N/A

Table 6. Review of Past Reports Showing Assessment Using the DDW-J 2004 Scale. (Continued)

Past report		1	2	3	4
	Reference	15	10	11	12
Total score and assessment in DILI patients	Total score (range)	7 (2-9)	6 (1-11)	7 (0-13)	7 (2-14)
	≤ 2: low possibility	1 (1.6%)	13 (3.6%)	34 (2.1%)	1 (0.3%)
	3 and 4: possible	4 (6.3%)	42 (11.4%)	166 (10.0%)	18 (5.9%)
	≥ 5: high possibility	58 (92.1%)	311 (85.0%)	1,473 (87.9%)	288 (93.8%)
Total score and assessment in non-DILI patients	Total score (range)	1 (-3 - 4)	N/A	N/A	N/A
	≤ 2: low possibility	37 (88.1%)	N/A	N/A	N/A
	3 and 4: possible	5 (11.9%)	N/A	N/A	N/A
	≥ 5: high possibility	0	N/A	N/A	N/A
Diagnostic ability of the DDW-J 2004 scale (cut-off score ≥ 3)	Sensitivity	98.4%	96.4%	98.0%	99.7%
	Specificity	88.1%	N/A	N/A	N/A
	PPV	92.5%	N/A	N/A	N/A
	NPV	97.4%	N/A	N/A	N/A

DILI: drug-induced liver injury, ALT: alanine aminotransferase, ALP: alkaline phosphatase, DLST: drug-induced lymphocyte stimulation test, PPV: positive predictive value, NPV: negative predictive value

Differences between the DDW-J 2004 scale and updated RUCAM

It should be noted that the RUCAM scale (7) and DDW-J 2004 scale (8, 11) have different purposes and uses. Nevertheless, the DDW-J 2004 scale appears to be less well-known worldwide than the RUCAM scale, considering the number of citations in reviews and research. Although the DDW-J 2004 scale was published in English (8), it remains unreadable online; this may be one of the obstacles hampering its global recognition. Note that a review article published in 2009 containing the key table of the DDW-J 2004 scale is available on the web (11).

The RUCAM scale was introduced in 1993 and updated in 2016 (21) with the purpose of assessing liver damage caused by Chinese herbs. The configuration of diagnostic items in the updated version is similar to that in the original version. Regarding alcohol intake, which is considered to be a risk factor of DILI, the amount of alcohol was determined by gender. However, the differential diagnosis was further strengthened. The seven causes of HAV, HBV, HCV, HEV, biliary tract disease, alcoholism, and a recent history of acute hypotension are categorized into group I, while the five causes of complications of underlying diseases (sepsis, metastatic malignancy, AIH, chronic HBV or HCV infection, PBC, primary sclerosing cholangitis, and genetic liver diseases), CMV, EBV, herpes simplex virus, and varicella-zoster virus are categorized into group II. If both groups are evaluated, the highest score that can be obtained is 2. When group I causes are completely excluded, only 1 point can be obtained, and if fewer than five diseases from group I are considered, 2 points are deducted (21). In addition, the evaluation methods for the differential diagnosis are also specified in great detail, and some of them, e.g. anti-HEV-IgM, HEV-RNA, and anti-CMV-IgG, are not common in Ja-

pan. A checklist of these diseases was included as an appended table.

The RUCAM scale aims to be a common basic tool for clinical, regulatory, publication, and expert purposes (7, 21, 22). While it is a more precise and strict causality assessment scale than the DDW-J 2004 scale (21-23), it may be inconvenient for daily clinical use for evaluation of DILI by non-hepatologists. At the DDW-J 2002 symposium that proposed a scale based on the RUCAM scale, the diagnostic item regarding “concomitant drug” in the RUCAM scale was deleted, as it carried a risk of underestimating DILI in Japanese patients, who commonly use concomitant drugs (1, 2). Indeed, 180 of 230 (78.3%) patients in this study were receiving concomitant drugs. The items for differentiation were simplified to eight common liver diseases: HAV, HBV, HCV, biliary tract disease, shock liver, EBV, and CMV. Subsequently, to assess allergic reactions, eosinophilia and DLST were added as diagnostic items (1).

The DDW-J 2002 causality assessment scale was evaluated to confirm its ability to accurately diagnose DILI in Japanese cases that had been overlooked using the RUCAM scale (2). Thereafter, the DDW-J 2004 scale was proposed based on the DDW-J 2002 causality assessment scale (8). In Japan, the DDW-J 2004 scale has commonly been used as a unified standard for the diagnosis of, research into, and case reporting for DILI. One of the purposes of the DDW-J 2004 scale is to function as a simple scale for use by clinicians other than hepatologists (8). It is accompanied by a detailed user manual and includes a recommendation that cases that are difficult to diagnose or have severe liver injury be promptly referred to a hepatologist (8). As mentioned above, using the DDW-J 2004 scale, inadequate differential diagnoses can reduce scores, but typical DILI patients will not be overlooked if their basic information, such as the time to the onset after administration, course after cessation of the drug,

risk factors, and previous information on hepatotoxicity of the drug, are met (11, 12, 15). Therefore, if the DDW-J 2004 scale is updated in the future, the updated RUCAM should be cited carefully to avoid making the diagnosis of DILI in Japan more complicated than it needs to be.

Conclusion

The DDW-J 2004 scale maintains a stable diagnostic ability for typical DILI, regardless of differences in patient background characteristics between eras and differences in verification methods. Nevertheless, the medical cost for the evaluation should also be considered, as well as the fact that inadequate differential diagnoses may affect scoring. While new drugs do not influence the diagnosis, new types of DILI, such as irAEs, must be addressed. Therefore, it may be time to consider updating the DDW-J 2004 scale.

The authors state that they have no Conflict of Interest (COI).

References

1. Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. *Hepatol Res* **27**: 192-195, 2003.
2. Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan - comparison with two previous scales. *Hepatol Res* **30**: 148-154, 2004.
3. Masumoto T, Horiike N, Abe M, et al. Diagnosis of drug-induced liver injury in Japanese patients by criteria of Consensus Meetings in Europe. *Hepatol Res* **25**: 1-7, 2003.
4. Hoofnagle JH, Björnsson ES. Drug-induced liver injury - types and phenotypes. *N Engl J Med* **381**: 264-273, 2019.
5. Andrade RJ, Aithal GP, Björnsson ES, et al. EASL clinical practice guidelines: drug-induced liver injury. *J Hepatol* **70**: 1222-1261, 2019.
6. Benichou C. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. *Int J Clin Pharmacol Ther Toxicol* **28**: 317-322, 1990.
7. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. *J Clin Epidemiol* **46**: 1323-1330, 1993.
8. Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. *Hepatol Res* **32**: 250-251, 2005.
9. Takikawa H, Onji M, Takamori Y, et al. Proposal of diagnostic criteria for drug-induced liver injury revised by the DDW-J 2004 Workshop. *Kanzo* **46**: 85-90, 2005 (In Japanese).
10. Takikawa H. Recent status of drug-induced liver injury. *Hepatol Res* **39**: 1-6, 2009.
11. Takikawa H, Murata Y, Horiike N, Fukui H, Onji M. Drug-induced liver injury in Japan: an analysis of 1676 cases between 1997 and 2006. *Hepatol Res* **39**: 427-431, 2009.
12. Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. *Hepatol Res* **49**: 105-110, 2019.
13. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. *Hepatology* **51**: 2117-2126, 2010.
14. Watanabe M, Shibuya A, Satomichi A, et al. Diagnostic value of drug lymphocyte stimulation test and evaluation of diagnostic criteria for drug induced liver injury. *Kanzo* **42**: 448-454, 2001 (In Japanese).
15. Watanabe M, Shibuya A, Miura Y, et al. Validity study of DDW-J 2004 scoring scale for drug-induced liver injury. *Kanzo* **48**: 219-226, 2007 (In Japanese).
16. Danan G, Teschke R. Roussel uclaf causality assessment method for drug-induced liver injury: present and future. *Front Pharmacol* **10**: 853, 2019.
17. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. *J Hepatol* **31**: 929-938, 1999.
18. de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. *Clin Gastroenterol Hepatol* **15**: 103-112, 2017.
19. Farrell GC. Drugs and steatohepatitis. *Semin Liver Dis* **22**: 185-194, 2002.
20. De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. *J Hepatol* **68**: 1181-1190, 2018.
21. Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. *Int J Mol Sci* **17**: 14, 2016.
22. Danan G, Teschke R. Drug-Induced liver injury: why is the Roussel Uclaf Causality Assessment Method (RUCAM) still used 25 years after its launch? *Drug Saf* **41**: 735-743, 2016.
23. Teschke R. Idiosyncratic DILI: analysis of 46,266 cases assessed for causality by RUCAM and published from 2014 to early 2019. *Front Pharmacol* **23**: 730, 2019.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).